BOSTON, September 25, 2026 — In addition to the nine studies that will be featured in news briefings at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, the following studies on advances in radiation medicine and cancer care were recommended by ASTRO experts as highlights for news professionals.
These studies will be presented during ASTRO's Annual Meeting, taking place in Boston and online, September 26-30. ASTRO experts are available to provide outside commentary; contact ASTRO's media relations team to schedule an interview.
Abstract 1 : Hypofractionated Versus Conventional Fractionated Postmastectomy Radiotherapy in High-Risk Breast Cancer: 10-Year Outcomes from a Phase 3 Randomized Trial ( Author Details , Session Details )
Abstract 2 : Initial Results of NRG Oncology NRG-GI003: A Phase III Randomized Trial of Protons versus Photons for Hepatocellular Carcinoma ( Author Details , Session Details )
Abstract 7 : Five-Year Results of a Phase 3 Trial of Hypofractionated versus Conventional Postprostatectomy Radiotherapy: NRG Oncology GU003 ( Author Details , Session Details )
Abstract 9 : 6-year Overall Survival of Nivolumab Following Stereotactic Ablative Radiotherapy in Early-Stage Non–Small Cell Lung Cancer: Randomized I-SABR Trial ( Author Details , Session Details )
Abstract 11 : Stereotactic Body Radiation Therapy (SBRT) and Comprehensive Metastasis-Directed Therapy for Ewing Sarcoma Patients Enrolled on AEWS1221: A Report from the Children's Oncology Group (COG) ( Author Details , Session Details )
Abstract 149 : Impact of Patient Navigation in a Cancer Center-Community Partnership on Short-Course Radiation Therapy Access for African-American Breast Cancer Patients: Early Results of the Navigator-Assisted Hypofractionation (NAVAH) Program ( Author Details , Session Details )
Abstract 294 : Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Small (≤2 cm) HCCs: Interim Results from A Prospective, Single-Center, Non-Inferiority Randomized Clinical Trial (ChiCTR2000039404) ( Author Details , Session Details )
LBA 05 : Chemoradiotherapy (CRT) Followed By Consolidation Durvalumab (D) In Patients (pts) with Resectable or Borderline Resectable Stage IIB–IIIB NSCLC Who Become Unresectable during Neoadjuvant Treatment (Tx): Results from the Phase 2 MDT-Bridge Study ( Author Details , Session Details )
ASTRO's Annual Meeting, the leading global conference in radiation oncology, features pivotal studies in radiation medicine for patients with cancer and other diseases, with speakers and sessions spotlighting next-generation approaches that are making treatments safer, more effective and more personalized.
Led by ASTRO President Neha Vapiwala, MD, FASTRO, the meeting is expected to attract 10,000 oncologists, clinicians, researchers and other health care professionals from around the globe. The meeting's theme, "Data to Dialogue: Communicating Radiotherapy's Value to Advance Care," focuses on fostering meaningful conversations with patients and other key stakeholders about the far-reaching uses and benefits of radiation therapy.
The meeting will feature more than 2,500 abstract presentations, keynote addresses from former Commissioner of the U.S. Food and Drug Administration Scott Gottlieb, MD, and award-winning oncologist and bioethicist Ezekiel Emanuel, MD, PhD, and educational expert panels on timely issues in cancer care such as artificial intelligence and radiopharmaceutical therapy. More information can be found on ASTRO's Annual Meeting website .
ABOUT ASTRO
